Samsung Biologics Shares Rise on Growth Momentum – What to Watch Samsung Biologics shows strong growth in revenue and operating profit, supported by M&A expansion like PolyPeptide, but key risk is renewed production disruptions and integration costs. 2026년 07월 22일 English
